8C5R

Omicron B.1.1.529 2 RBD up conformation

8C5R の概要

• エントリーDOI: 10.2210/pdb8c5r/pdb
• EMDBエントリー: 16441
• 分子名称: Spike glycoprotein (1 entity in total)
• 機能のキーワード: covid-19, spike trimer, omicron, b.1.1.529, viral protein
• 由来する生物種: Alphacoronavirus
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 354580.78

構造登録者

Raghavan, S.S.R.,Walker, M.R.,Salanti, A.,Barfod, L.K.,Wang, K.T. (登録日: 2023-01-10, 公開日: 2024-01-24, 最終更新日: 2025-07-09)

主引用文献

Walker, M.R.,Underwood, A.,Bjornsson, K.H.,Raghavan, S.S.R.,Bassi, M.R.,Binderup, A.,Pham, L.V.,Ramirez, S.,Pinholt, M.,Dagil, R.,Knudsen, A.S.,Idorn, M.,Soegaard, M.,Wang, K.,Ward, A.B.,Salanti, A.,Bukh, J.,Barfod, L.
Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages.
Commun Biol, 7:1239-1239, 2024

PubMed Abstract: The continuous emergence of SARS-CoV-2 variants of concern has rendered many therapeutic monoclonal antibodies (mAbs) ineffective. To date, there are no clinically authorized therapeutic antibodies effective against the recently circulating Omicron sub-lineages BA.2.86 and JN.1. Here, we report the isolation of broad and potent neutralizing human mAbs (HuMabs) from a healthcare worker infected with SARS-CoV-2 early in the pandemic. These include a genetically unique HuMab, named K501SP6, which can neutralize different Omicron sub-lineages, including BQ.1, XBB.1, BA.2.86 and JN.1, by targeting a highly conserved epitope on the N terminal domain, as well as an RBD-specific HuMab (K501SP3) with high potency towards earlier circulating variants that was escaped by the more recent Omicron sub-lineages through spike F486 and E484 substitutions. Characterizing SARS-CoV-2 spike-specific HuMabs, including broadly reactive non-RBD-specific HuMabs, can give insight into the immune mechanisms involved in neutralization and immune evasion, which can be a valuable addition to already existing SARS-CoV-2 therapies.

PubMed: 39354108
DOI: 10.1038/s42003-024-06951-7

実験手法

ELECTRON MICROSCOPY (3.7 Å)